Quibim Appoints Jeanne Bolger As Independent Director & Advisor To Accelerate Growth In Life Sciences
New enhancements deliver advanced 3D visualization capabilities and an end-to-end prostate cancer management solution.
27 January 2026, London – Quibim, the global pioneer in imaging biomarkers for precision medicine, is pleased to announce the appointment of Dr. Jeanne Bolger, MB BCh BAO, as Independent Director & Advisor. This appointment reflects Quibim’s commitment to accelerating its development within the life sciences sector and strengthening collaborations with leading pharmaceutical companies.
Dr Bolger brings decades of experience as a Senior Leader, an Independent Director and Advisor in the healthcare and life sciences industries. Having held senior roles in Business Development at leading companies such as GSK and Johnson & Johnson, over a decade leading Corporate Venture at JJDC (Johnson & Johnson’s venture capital arm), and Board Director roles at VC-backed and listed companies , she has developed deep expertise in strategic partnerships, business development, strategy and governance, which will be instrumental in advancing Quibim’s mission to transform imaging into a catalyst for precision health.
Quibim’s AI-powered, imaging-based solutions enable pharmaceutical companies to predict which patients will respond to a drug, identify suitable candidates for clinical trials, stratify patients by risk, and accelerate drug development programs. These capabilities are already driving innovation across oncology, immunology, and neurology.
Ángel Alberich-Bayarri, CEO of Quibim said, “Jeanne brings a unique perspective and proven track record in life sciences that will help us unlock new opportunities with pharmaceutical partners. Her guidance will be key as we scale our AI-imaging solutions to accelerate drug development and deliver more personalised care. We’re excited to work together to push the boundaries of precision medicine.”
Dr Bolger joins a distinguished Board of Directors that includes leaders from global healthcare and investment sectors. Her appointment marks a significant milestone in Quibim’s strategy to expand its footprint in life sciences and deliver cutting-edge imaging solutions to pharmaceutical partners worldwide.
The Board of Directors is now composed of seven members:
- Ángel Alberich-Bayarri, CEO & Co-Founder of Quibim
- Tom Tynes, Founder of T2 MedTech (Independent Director)
- Pierre Socha, Partner at Amadeus Capital
- Romain Lavault, General Partner at Partech
- Guillem Masferrer, Partner at Asabys Partners
- José Mesa, Partner at Columbus Venture Partners and Buenavista’s representative on the Board
- Jeanne Bolger, Independent Director
About Quibim
Quibim is a company designing pioneering tools that unlock imaging data to improve patient outcomes. With offices in New York (United States), Cambridge (United Kingdom), Valencia, Madrid, and Barcelona (Spain), the company was born from the ambition of turning imaging into a catalyst for precision health. Quibim leads the forefront of imaging biomarkers research in life sciences, pioneering the development of advanced algorithms that transform imaging data into actionable predictions in oncology, immunology, and neurology. The company leverages the capabilities of MRI, CT, and PET imaging to create regulatory-cleared Medical Devices that are seamlessly integrated into the workflows of healthcare providers worldwide. For more information, visit www.quibim.com.